[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Patel SR, Papadopolous N, Raymond AK, Donato M, Seong CM, Yasko AW, Lewis VO, Lin PP, Champlin R, Benjamin RS: A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. Cancer; 2004 Jul 1;101(1):156-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
  • BACKGROUND: The authors evaluated the efficacy and toxicity of cisplatin, ifosfamide, and doxorubicin with peripheral blood stem cell (PBSC) support in adult patients with osteosarcomas and variants with a poor prognosis.
  • METHODS: Between December 1994 and January 2001, 37 patients (20 males and 17 females) with a median age of 38 years (range, 18-63 years) entered the study.
  • Ten patients had pelvic osteosarcomas (OS), 6 had malignant fibrous histiocytomas, 5 had metastatic OS, and 16 had miscellaneous histologies.
  • The median PBSC collection was 17.5 x 10(6)/kg (range, 13.2-90.8 x 10(6)/kg) with a median of 1 apheresis (range, 1-2 aphereses).
  • Six patients required early discontinuation of therapy due to toxicities, two patients developed progressive disease, and one patient was deemed unresectable.
  • The median time to progression (TTP) and overall survival by Kaplan-Meier estimates for all 37 patients was 19 months and 49 months, respectively.
  • CONCLUSIONS: The authors accomplished the objective of improving the rate of necrosis with intensification of preoperative therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Hematopoietic Stem Cell Mobilization. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease Progression. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Granulocyte Colony-Stimulating Factor / pharmacology. Hematopoietic Stem Cells / drug effects. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15222001.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


2. Neverauskiene S, Machtejeviene E, Vaitkiene D, Juodzbaliene EB: [Disseminated ovarian, bone, and bone marrow metastases from gastric cancer]. Medicina (Kaunas); 2006;42(11):923-31
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early detection and destruction of circulating malignant cells before developing metastases may markedly improve survival of these patients.
  • Krukenberg tumors (metastases of non-gynecological origin in the ovaries) usually are circular cell carcinomas of gastric cancer.
  • Hematological paraneoplastic disorders can be miscellaneous: they usually manifest as anemia of various origin, as leucocytosis in half of the patients, as leukemoid reactions in one-third of the patients, and as hemolysis and thrombocytopenia in half of the patients (often with disseminated intravascular coagulation).
  • Currently, chemotherapy is the most effective treatment for outspread gastric cancer.
  • Unfortunately, there is no exclusively effective scheme for treatment.
  • Lymph node metastases are more sensitive to chemotherapy than primary gastric cancer, while in contrary, hepatic metastases are less sensitive than primary gastric cancer.
  • [MeSH-minor] Biopsy. Female. Humans. Lymphatic Metastasis. Middle Aged. Prognosis. Stomach / pathology. Time Factors


3. Mekhail T, Hutson TE, Elson P, Budd GT, Srkalovic G, Olencki T, Peereboom D, Pelley R, Bukowski RM: Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies. Cancer; 2003 Jan 1;97(1):170-8
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnoses were as follows: Eleven patients had nonsmall cell lung carcinoma, 3 patients had carcinoma of the bladder, 3 patients had renal carcinoma, 2 patients had adrenal carcinoma, 5 patients had unknown primary tumors, and 9 patients had miscellaneous malignancies.
  • Fifty-nine percent of patients had received prior chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Aged. Female. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Male. Maximum Tolerated Dose. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12491518.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


Advertisement
4. Dreyer ZE, Kadota RP, Stewart CF, Friedman HS, Mahoney DH, Kun LE, McCluggage CW, Burger PC, Kepner J, Heideman RL, Pediatric Oncology Group: Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237. Neuro Oncol; 2003 Oct;5(4):261-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237.
  • For this reason, the Pediatric Oncology Group conducted a Phase 2 trial of IDA for children with recurrent or progressive brain tumors.
  • Patients were stratified by tumor types into 6 categories: stratum 1, low-grade astrocytoma; stratum 2, malignant glioma (glioblastoma multiforme and anaplastic astrocytoma); stratum 3, medulloblastoma; stratum 4, brainstem glioma; stratum 5, ependymoma; and stratum 6, miscellaneous malignant tumors not included in the previous diagnoses.
  • Cycles were repeated at approximately 21-day intervals until patients developed progressive disease or had completed 6 cycles with stable or improved disease.
  • Most patients developed progressive disease; however, in 21 patients with medulloblastoma there was 1 partial response, and 6 patients had stable disease (SD) that in 4 patients lasted more than 20 weeks.
  • Only 1 patient developed reduced cardiac function.
  • The systemic clearance data for IDA and IDOL were nearly identical to those published on patients with leukemia, and the plasma elimination of the IDOL metabolite was substantially longer than that of the parent drug IDA.
  • We conclude from this data and from that in nonhuman primates that it is unlikely that IDA, daunomycin, or other related anthracyclines will be useful for treating primary CNS tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Idarubicin / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14565163.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC1920677
  •  go-up   go-down


5. Konovalov AN, Pitskhelauri DI: Principles of treatment of the pineal region tumors. Surg Neurol; 2003 Apr;59(4):250-68

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Principles of treatment of the pineal region tumors.
  • BACKGROUND: A pineal region tumor is an uncommon deep-seated, heterogeneous group of mass lesions of the brain, and the management strategy of any types of these tumors remains controversial.
  • METHODS: From 1976 to 1999 about 700 patients with tumors of the pineal region and posterior third ventricle were managed at the Burdenko Neurosurgery Institute.
  • In more than 330 cases the tumor was removed.
  • In this paper we present results of 287 patients with histologically verified pineal region tumors for the period from 1976 to 1999.
  • All of them had verified tumor histology, excluding only five cases in which stereotactic biopsy procedures were uninformative.
  • There are four main groups of tumors: the germ cell tumors-87 (31%); the pineal parenchymal tumors-75 (27%); the glial tumors-77 (27%); and miscellaneous-43 (15%).
  • There were 255 surgical procedures for tumor removal performed in 244 and stereotactically guided biopsies in 61 patients, 168 (58%) with obstructive hydrocephalus who underwent cerebrospinal fluid shunting.
  • Radiation therapy was administered in 145 (51%) and chemotherapy in 16 patients.
  • A total tumor removal was achieved in 148 operations (58%), subtotal in 74 (29%) and partial in 33 (13%).
  • The projected 5-year and 10-year survival rates for patients with malignant pineal tumors, who received irradiation after tumor resection or underwent radiation therapy alone, were: 95% and 88% for pure germinomas, 80% and 50% for high grade gliomas, 44% and 0% for malignant pineal parenchymal tumors, and 20% and 0% for malignant germ cell tumors, respectively.
  • CONCLUSIONS: Benign pineal tumors should be cured with surgery alone.
  • Malignant tumors should be treated with aggressive resection followed with irradiation and chemotherapy.
  • Pure germinomas, which are exquisitely radiosensitive, can be cured by conventional radiation therapy alone.
  • [MeSH-minor] Adolescent. Adult. Animals. Biopsy. Child. Child, Preschool. Female. Humans. Hydrocephalus / etiology. Male. Middle Aged. Prognosis. Retrospective Studies. Stereotaxic Techniques. Survival. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12748006.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Ismail-Zade RS, Zhavrid EA, Aleĭnikova OV, Potapnev MP, Belevtsev MV, Isaĭkina IaI, Vashkevich EP, Savitskiĭ VP: [Use of LAK-cells and systemic chemotherapy with hyperthermia in the management of chemo-resistant tumors]. Vopr Onkol; 2010;56(6):681-6
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of LAK-cells and systemic chemotherapy with hyperthermia in the management of chemo-resistant tumors].
  • Tentative results of LAK-cell and whole-body hyperthermia (WBH) were evaluated in 19 children with advanced chemorefractory tumors.
  • LAK-cells were obtained by extracorporeal incubation of peripheral blood lymphocytes: a germ-cell rhabdomyosarcoma was detected in 4, Askin's tumor--2--2, renal cell carcinoma--2 and miscellaneous--7.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hyperthermia, Induced. Immunotherapy, Adoptive. Killer Cells, Lymphokine-Activated. Neoplasms / therapy
  • [MeSH-minor] Adolescent. Body Temperature. Carcinoma, Renal Cell / therapy. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Neoplasms, Germ Cell and Embryonal / therapy. Neuroectodermal Tumors / therapy. Rhabdomyosarcoma, Embryonal / therapy. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21395124.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Kelner MJ, McMorris TC, Rojas RJ, Estes LA, Suthipinijtham P: Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil. Invest New Drugs; 2008 Oct;26(5):407-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil.
  • The novel agent Irofulven (HMAF, NSC 683863) has demonstrated significant antitumor activity against solid tumors in various xenograft models and human clinical trials.
  • The antitumor potential of combining irofulven with 72 different anti-metabolite, enzyme inhibiting, and miscellaneous agents was investigated in this study.
  • Other anti-metabolites, enzyme inhibitors, and a variety of miscellaneous agents failed to interact beneficially when administered in combination with irofulven.
  • The therapeutic activity of irofulven is enhanced considerably when irofulven is combined with select anti-metabolite agents, and further clinical evaluation of these combinations is warranted.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Enzyme Inhibitors / administration & dosage. Fluorouracil / administration & dosage. Sesquiterpenes / administration & dosage
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Synergism. Female. Humans. Lung Neoplasms / drug therapy. Mice. Mice, Inbred BALB C. Random Allocation. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1997 May-Jun;17(3C):1965-71 [9216653.001]
  • [Cites] Prostate. 2004 Apr 1;59(1):22-32 [14991863.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jan;71(2):133-43 [11883439.001]
  • [Cites] Invest New Drugs. 2006 Jul;24(4):311-9 [16683074.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1492-9 [14977853.001]
  • [Cites] Int J Oncol. 1999 Dec;15(6):1191-6 [10568827.001]
  • [Cites] Invest New Drugs. 2002 Aug;20(3):271-9 [12201490.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24 [7932806.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5604-13 [15328203.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2A):559-64 [12014623.001]
  • [Cites] Biochem Pharmacol. 1997 Dec 1;54(11):1181-93 [9416969.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):36-42 [15685033.001]
  • [Cites] J Am Chem Soc. 2007 Feb 21;129(7):2101-11 [17256933.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4936-40 [7585533.001]
  • [Cites] Biochem Pharmacol. 1994 Jul 19;48(2):403-9 [8053936.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Apr;57(4):491-9 [16075278.001]
  • [Cites] J Nat Prod. 1996 Sep;59(9):896-9 [8864242.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26553-64 [11953432.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):55-61 [16260029.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2A):1299-307 [10368691.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2499-504 [12171875.001]
  • [Cites] J Med Chem. 2006 Apr 20;49(8):2593-9 [16610802.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3377-85 [15161692.001]
  • [Cites] Cancer Invest. 1999;17(2):95-101 [10071592.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(3):235-40 [10453725.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Jul-Aug;22(4):306-14 [10959900.001]
  • [Cites] Int J Cancer. 1987 Jul 15;40(1):46-52 [3596831.001]
  • [Cites] Pharmacol Rev. 1995 Jun;47(2):331-85 [7568331.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;27(4):278-84 [1998983.001]
  • [Cites] J Clin Oncol. 2000 Dec 15;18(24):4086-97 [11118470.001]
  • [Cites] Curr Biol. 2000 Apr 20;10(8):479-82 [10801416.001]
  • [Cites] Anticancer Res. 1995 May-Jun;15(3):867-71 [7645973.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4529-34 [10493501.001]
  • [Cites] Anticancer Drugs. 1996 May;7(3):339-43 [8792009.001]
  • [Cites] Anticancer Res. 2001 May-Jun;21(3B):1789-94 [11497260.001]
  • [Cites] Cancer Treat Rep. 1987 Mar;71(3):297-304 [3815395.001]
  • [Cites] Biochem Pharmacol. 2000 May 15;59(10):1217-26 [10736422.001]
  • [Cites] Surgery. 1999 May;125(5):536-44 [10330943.001]
  • [Cites] Invest New Drugs. 2004 Aug;22(3):343-9 [15122083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1885-90 [10677551.001]
  • [Cites] J Biol Chem. 2004 Sep 17;279(38):39584-92 [15269203.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3186-9 [3472654.001]
  • [Cites] Biochem J. 2001 Nov 1;359(Pt 3):537-46 [11672427.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):279-83 [9000568.001]
  • [Cites] Blood. 1997 Jul 1;90(1):471 [9207485.001]
  • [Cites] Biochem Pharmacol. 1999 Dec 1;58(11):1713-21 [10571245.001]
  • [Cites] Leukemia. 2000 Jan;14(1):136-41 [10637489.001]
  • [Cites] Oncogene. 2003 Sep 1;22(37):5834-47 [12947390.001]
  • [Cites] Biochem Pharmacol. 2003 Feb 15;65(4):503-13 [12566077.001]
  • [Cites] Anticancer Drugs. 1999 Oct;10(9):837-44 [10587294.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 May;49(5):412-8 [11976836.001]
  • [Cites] Anticancer Drugs. 2000 Mar;11(3):217-24 [10831281.001]
  • [Cites] Eur J Cancer. 2000 Dec;36(18):2430-6 [11094320.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1049-53 [10070962.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Aug;126(8):461-7 [10961389.001]
  • [Cites] Biochem Pharmacol. 2007 Feb 15;73(4):469-80 [17118344.001]
  • [Cites] Invest New Drugs. 1996;14(2):161-7 [8913837.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):908-13 [9797706.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 May;55(5):411-9 [15503024.001]
  • [Cites] DNA Repair (Amst). 2002 Dec 5;1(12):1027-38 [12531012.001]
  • (PMID = 18227973.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Enzyme Inhibitors; 0 / Sesquiterpenes; 0W860991D6 / Deoxycytidine; 6B799IH05A / irofulven; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Mikuz G: [WHO classification of testicular tumors]. Verh Dtsch Ges Pathol; 2002;86:67-75
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [WHO classification of testicular tumors].
  • The most important is obviously the precursor lesion of germ cell tumors, which has been called "intratubular malignant germ cells".
  • Such atypical cells appear in the tubules adjacent to the germ cell tumors, in some few cases (6%) also in the contra lateral healthy gonad and rarely in infertile men (1%).
  • The precursor lesion can progress to franc germ cell tumor starting probably with seminoma, which still maintain the capability of differentiation (pluripotente cells) in all other types of non-seminomatous germ cell tumors.
  • This lesion is missed in germ cell tumors of childhood and in spermatocytic seminomas, both seem to have a histogenetic history rather different from the other germ cell in adults.
  • Most of the new diagnoses are subtypes--called "variants"--of well known tumors.
  • Spermatocytic seminomas are perfectly benign tumors but they become a life threatening disease when combined with sarcomas (new entity).
  • This is a harmless name for an extremely dangerous tumor in which one tissue overgrows the other and gives rise to somatic type sarcomas or carcinomas.
  • Such tumors do not respond like germ cell tumors to the usual chemotherapy.
  • Treatment should be tailored according to that used in standard management of the respective sarcoma or carcinoma.
  • In the comments it is mentioned that the testis carcinoid could be a part of teratoma, but the diagnosis is listed in the group of "miscellaneous" tumors together with tumors of ovarian epithelial type.
  • This is a very questionable decision because the normal testis does not contain neuroendocrine cells from which carcinoids would have to be able to develop.
  • "Large cell calcifying Sertoli cell tumour" has been recently described and can be sporadic or inherited.
  • This morphologically peculiar tumor can be part of the Swiss syndrome also called Carney's complex.
  • The patients have cardiac myxomas, spotty skin pigmentation, hormone active nodular hyperplasia of the adrenals and soft tissue myxomas.
  • In contrast to gonadoblastoma, however, these tumors occur in testes of genotypic and phenotypic normal males.
  • For the therapy of germ cell tumor an assessment of risk factors found by the pathologists is extremely important.
  • The most important independent predictors of relapse are tumor invasion of blood or lymph-vessels, absence of yolk sac elements and the presence of an embryonal carcinoma component.
  • In the absence of such predictors a surveillance policy allows some patients to forgo chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12647353.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


9. Mulne AF, Ducore JM, Elterman RD, Friedman HS, Krischer JP, Kun LE, Shuster JJ, Kadota RP: Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. J Pediatr Hematol Oncol; 2000 Jan-Feb;22(1):41-4
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study.
  • PURPOSE: Children with recurrent or progressive central nervous system (CNS) tumors have an unfavorable prognosis.
  • Patients in six different brain tumor strata were accrued.
  • RESULTS: The response rates (complete or partial responses) were as follows: astrocytoma 2 of 10, malignant glioma 1 of 19, medulloblastoma 0 of 18, brainstem tumor 0 of 12, ependymoma 1 of 7, and miscellaneous histologic types 0 of 12.
  • CONCLUSION: Low-dose oral MTX showed no significant activity against malignant glioma, medulloblastoma, brainstem tumors, and miscellaneous histologic types.
  • This regimen will not be recommended for front-line therapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Brain Neoplasms / drug therapy. Methotrexate / therapeutic use. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10695820.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-03161; United States / NCI NIH HHS / CA / CA-29691; United States / NCI NIH HHS / CA / CA-69177; etc
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Hurwitz CA, Strauss LC, Kepner J, Kretschmar C, Harris MB, Friedman H, Kun L, Kadota R: Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. J Pediatr Hematol Oncol; 2001 Jun-Jul;23(5):277-81
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
  • PURPOSE: To assess the efficacy and define the toxicity of paclitaxel given at a dosage of 350 mg/m2 every 3 weeks as a 24-hour continuous infusion to children with recurrent or progressive primary brain tumors.
  • PATIENTS AND METHODS: Seventy-three eligible patients, ages 4 months to 19 years, with progressive or recurrent primary brain tumors were treated according to a Pediatric Oncology Group (POG) phase II protocol with paclitaxel (POG 9330).
  • Tumor histologic strata included: astrocytoma (n = 4), malignant glioma (n = 13), medulloblastoma (n = 16), brain stem glioma (n = 15), ependymoma (n = 13), and miscellaneous histologies (n = 12).
  • All patients had previous histologic confirmation of a primary intracranial or spinal cord tumor with magnetic resonance imaging or computed tomography documentation of unequivocally measurable progressive or recurrent disease.
  • All patients had received previous therapy including surgery, radiation therapy, and/or chemotherapy, but no patient had been previously treated on more than one phase II trial.
  • Patients were allowed to continue therapy for a total of 18 cycles in the absence of progressive disease or unacceptable toxicity.
  • RESULTS: Seventy-five patients were enrolled onto the POG 9330 protocol; two ineligible patients were removed from the study before receiving any therapy.
  • CONCLUSION: Paclitaxel is well tolerated in children with recurrent or progressive brain tumors at this dosage and schedule and may result in short-term disease stabilization in this patient population.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adolescent. Astrocytoma / drug therapy. Astrocytoma / pathology. Child. Child, Preschool. Dexamethasone / therapeutic use. Disease Progression. Drug Hypersensitivity / prevention & control. Ependymoma / drug therapy. Ependymoma / pathology. Female. Glioma / drug therapy. Glioma / pathology. Humans. Immunosuppressive Agents / therapeutic use. Infant. Infratentorial Neoplasms / drug therapy. Infratentorial Neoplasms / pathology. Infusions, Intravenous. Male. Medulloblastoma / drug therapy. Medulloblastoma / pathology. Nausea / chemically induced. Neoplasm Recurrence, Local. Neutropenia / chemically induced. Remission Induction. Salvage Therapy. Treatment Failure

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11464982.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03161; United States / NCI NIH HHS / CA / CA07431; United States / NCI NIH HHS / CA / CA15525; etc
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Immunosuppressive Agents; 7S5I7G3JQL / Dexamethasone; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


11. Ramnath N, Schwartz GN, Smith P, Bong D, Kanter P, Berdzik J, Creaven PJ: Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors. Cancer Chemother Pharmacol; 2003 Mar;51(3):227-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors.
  • We conducted a phase I trial to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT) and pharmacokinetics of AVLB given as a 1-h intravenous infusion once every 3 weeks in patients with advanced refractory solid tumors.
  • There were 12 males and 12 females with a median age of 60 years (range 27-75 years).
  • Diagnoses were non-small-cell lung cancer (NSCLC) (11), colorectal cancer (5), soft tissue sarcoma (4), and miscellaneous (4).
  • Patients had had a median of three prior chemotherapy regimens (range one to six).
  • The pharmacokinetics of AVLB were linear, and well characterized by a two-compartment model, with a mean clearance of 26.4 l/h per m(2) and median terminal half-life of 18 h.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacokinetics. Neoplasms / drug therapy. Vinblastine / adverse effects. Vinblastine / analogs & derivatives. Vinblastine / pharmacokinetics
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12655441.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16056
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 38390-45-3 / 3',4'-anhydrovinblastine; 5V9KLZ54CY / Vinblastine
  •  go-up   go-down


12. Azambuja E, Fleck JF, Batista RG, Menna Barreto SS: Bleomycin lung toxicity: who are the patients with increased risk? Pulm Pharmacol Ther; 2005;18(5):363-6
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bleomycin is an antibiotic drug with anticancer properties produced by Streptomyces verticillus [Cheson BD.
  • Pharmacology of cancer chemotherapy: miscellaneous chemotherapeutic agents.
  • Pharmacology of cancer chemotherapy: miscellaneous chemotherapeutic agents.
  • Pharmacology of cancer chemotherapy: miscellaneous chemotherapeutic agents.
  • The complex bleomycin-Fe has been the most studied because bleomycin joins the DNA and Fe at the same time, and release of free radicals happens in the presence of molecular oxygen [Hay J, Shahzeidi S, Laurent G.
  • Pharmacology of cancer chemotherapy: miscellaneous chemotherapeutic agents.
  • This drug has been used as cytostatic treatment of many malignant tumors, such as germ cell tumors, lymphomas, head and neck, and Kaposi's sarcomas [Chen XL, Li WB, Zhou AM et al.
  • Pharmacology of cancer chemotherapy: miscellaneous chemotherapeutic agents.

  • MedlinePlus Health Information. consumer health - Pulmonary Fibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15939315.001).
  • [ISSN] 1094-5539
  • [Journal-full-title] Pulmonary pharmacology & therapeutics
  • [ISO-abbreviation] Pulm Pharmacol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  • [Number-of-references] 37
  •  go-up   go-down


13. Goel R, Chen E, Welch S, Laurie S, Siu L, Jonker D, Srinivasan R, Wang L, Ivy P, Oza A, Princess Margaret Hospital Phase II Consortium: Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors.
  • : e13509 Background: E7389 (E) is a synthetic analogue of halichondrin B, an investigational tubulin-based antimitotic drug.
  • These two drugs exhibit synergistic cytotoxic effects against the H522 non-small cell lung cancer (NSCLC) xenografts.
  • METHODS: A phase I study of these two drugs in combination was initiated in patients with advanced solid tumours.
  • Two prior chemotherapy regimens for metastatic disease were allowed.
  • RESULTS: Patient characteristics: male 11/female 10; median age 59 (range 28-84); performance status 0 /1/2: n=1/13/7; prior chemotherapy 21, prior radiotherapy 7, prior immunotherapy 1; tumour types: ovarian cancer 3, endometrial cancer 3, NSCLC 3, gastric/esophageal adenocarcinoma 3, miscellaneous 9.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961270.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Goel R, Gertler S, Stewart DJ, Laurie S, Goss G, Reaume N, Cripps C, Bedard D, Rodgers A, Cutler D: Phase I study of temozolomide in conjunction with gemcitabine. J Clin Oncol; 2004 Jul 15;22(14_suppl):2127

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2127 Background: Temozolomide (TZ) is an oral alkylating agent used in the treatment of brain tumours, and malignant melanoma.
  • Gemcitabine (GC) is a nucleoside analogue clinically active versus several human tumors, including pancreatic cancer, breast cancer, non-small cell lung cancer, bladder cancer etc.
  • In vitro, these 2 drugs exhibit additive cytotoxic effects against the astrocytoma U373MG cell line.
  • METHODS: A phase I clinical study of these 2 drugs in combination was initiated.
  • Three prior chemotherapy regimens were allowed .
  • RESULTS: Patient characteristics: male 11/female 13; median age 55 (range 26-77); performance status 0 (n=3), 1 (n=14), and 2 (n=7); prior therapy: chemotherapy 21, radiotherapy 10, no prior anticancer therapy 2; tumour types: non-small cell lung 8, primary brain tumour 2, miscellaneous 14.
  • CONCLUSIONS: This chemotherapy regimen is well-tolerated.
  • Encouraging activity of the regimen is suggested in this group of heavily pre-treated patients with resistant tumours; 8 patients received more than 2 courses of therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28017087.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Huang HQ, Jiang WQ, Hu XH, Lin XB, Liu KF, Li YH, Lin Z, Shen WX, Chen Q, He YJ, Guan ZZ: [Preliminary study of lyophilized 10-hydroxycamptothecin in advanced or recurrent malignancies]. Ai Zheng; 2003 Dec;22(12):1334-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: 10-Hydroxycamptothecin (HCPT) is the inhibitor of topoisomerase I with anti-cancer effectiveness on several solid tumors.
  • The purpose of this study was to investigate the efficacy, toxicity, and proper dosage of TUOXI as single agent in treatment of advanced and recurrent solid tumors.
  • Among them, 18 patients were chemonaive and 42 were recurrent from chemotherapy; 22 patients with NSCLC, 12 nasopharyngeal carcinoma, 9 primary liver cancer, 9 colorectal carcinoma, 2 pancreatic carcinoma, and 6 miscellaneous malignancies.
  • Further clinical investigation on large number of solid tumors cases are warranted.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14693063.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 67656-30-8 / 10-hydroxycamptothecin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


16. Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C: Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol; 2003 Nov;4(11):670-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gestational trophoblastic diseases (GTD) consist of a group of neoplastic disorders arising from placental trophoblastic tissue after normal or abnormal fertilisation.
  • The WHO classification of GTD includes hydatidiform mole, invasive mole, choriocarcinoma, placental site trophoblastic tumour, and miscellaneous and unclassified trophoblastic lesions.
  • GTD have a varying potential for local invasion and metastases and they generally respond to chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14602247.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 73
  •  go-up   go-down


17. Tarasov VA, Vinogradova MV, Norbaev ShE, Sharov IuK, Stavrovietskiĭ VV, Adueva SA, Blium MB: [Combined cytoreductive surgery and intraoperative hyperthermic chemo-perfusion for peritoneal carcinomatosis: methods, postoperative features and end results]. Vopr Onkol; 2006;52(6):638-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peritoneal carcinomatosis is detected in 10-40% of patients with "first look" peritoneal tumors.
  • Median survival after chemotherapy is generally 2-6 months.
  • The study included 45 cases of surgery: gastric cancer (15), ovarian and cervical carcinoma ('17), colorectal cancer (8) and miscellaneous cancers involving advanced peritoneal carcinomatosis (5).
  • ISHTP procedure was carried out immediately after cytoreductive surgery including peritonectomy (Sugarbaker).
  • Cytoreductive surgery plus ISHTP protocol for peritoneal carcinomatosis increases survival time 3-fold and improves quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / therapy. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Female. Humans. Intraoperative Period. Male. Middle Aged. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Quality of Life. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy. Survival Analysis. Treatment Outcome. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338240.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


18. Levi AW, Potter SR, Schoenberg MP, Epstein JI: Clinical significance of denuded urothelium in bladder biopsy. J Urol; 2001 Aug;166(2):457-60
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We correlated the pertinent clinical features of patients with denuded bladder biopsies and/or specific pathological features of denuded bladder biopsy specimens with patient outcome in regard to bladder lesions to help predict the subsequent likelihood of diagnosing bladder carcinoma in a patient with a nondiagnostic denuded biopsy.
  • In remainder there were flat carcinoma in situ with or without other tumors (26%), high (20%) and low (14%) grade papillary tumors without carcinoma in situ and miscellaneous conditions (6%).
  • Parameters that did not correlate with the subsequent diagnosis of carcinoma in situ included cystoscopic impression, history of intravesical chemotherapy, sex, age, tissue inflammation, percent of tissue fragments with any denudation, number of denuded tissue fragments and percent of overall denuded epithelium.
  • Factoring in a history of other bladder tumor types in various combinations did not predict carcinoma in situ after denuded biopsy.
  • Carcinoma in situ developed within 24 months in 45% of patients in whom the denuded specimen was obtained by cold cup biopsy in contrast to none who underwent hot wire loop biopsy (p = 0.007).
  • Carcinoma in situ developed within 24 months in 75% of patients with a history of that condition and a subsequent cold cup biopsy showing denuded epithelium.
  • When the denuded biopsy sample was obtained by cold cup biopsy, particularly when associated with a history of carcinoma in situ, most cases represent neoplastic cell denudation and a high risk for subsequent carcinoma in situ.

  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11458047.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Gourley M, Williamson JS: Angiogenesis: new targets for the development of anticancer chemotherapies. Curr Pharm Des; 2000 Mar;6(4):417-39
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To ensure an adequate blood supply, tumor cells release angiogenic factors that are capable of promoting nearby blood vessels to extend vascular branches to the tumor.
  • In addition, larger tumors have been shown to release angiogeneic inhibitory factors that prevent blood vessels from sending branches to smaller, more distant tumors that compete for oxygen and nutrients.
  • Angiogenesis is a complex multistep biochemical process, and offers several potential molecular targets for non-cytotoxic anticancer therapies.
  • Strategies for exploiting tumor angiogenesis for novel cancer drug discovery include: (i) inhibition of proteolytic enzymes that breakdown the extracellular matrix surrounding existing capillaries;.
  • (iv) enhancement of tumor endothelial cell apoptosis.
  • There is also a host of miscellaneous agents that inhibit angiogenesis for which the specific mechanisms are not clear.
  • Several methods have been developed for measuring antiangiogenic activity both in vitro and in vivo.
  • Although there has been intensive research efforts focused at the phenomena of angiogenesis, as well as the search for antiangiogenic agents for more than two decades, many questions remain unanswered with regard to the overall biochemical mechanisms of the angiogenesis process and the potential therapeutic utility of angiogenic inhibitors.
  • Nevertheless potent angiogenic inhibitors capable of blocking tumor growth have been discovered, and appear to have potential for development into novel anticancer therapeutics.
  • However there are still hurdles to be overcome before these inhibitors become mainstream therapies.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / pharmacology. Neoplasms / drug therapy. Neoplasms / pathology. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology
  • [MeSH-minor] Animals. Humans. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10788590.001).
  • [ISSN] 1381-6128
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents
  • [Number-of-references] 120
  •  go-up   go-down


20. Brownstein CM, Mertens AC, Mitby PA, Stovall M, Qin J, Heller G, Robison LL, Sklar CA: Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study. J Clin Endocrinol Metab; 2004 Sep;89(9):4422-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we investigated which patient and treatment variables correlate with final height and change in height sd score (SDS) in a large cohort of cancer survivors treated with GH.
  • Diagnoses included: central nervous system tumors (n = 90), acute leukemia (n = 64), soft tissue sarcomas (n = 23), and miscellaneous (n = 6).
  • The median age at diagnosis of the primary cancer was 4.6 yr, and the median age at start of GH treatment was 11.3 yr.
  • Mean height SDS at start of GH therapy was -2.03 +/- 0.8, and the mean final height SDS was -1.48 +/- 0.10 (P < 0.001).
  • Risk factors associated with a final height of -2.0 sd or less included lower doses of GH and exposure to higher doses of spinal RT.
  • Thus, to maximize final height, our findings emphasize the importance of beginning GH therapy at the earliest bone age that is clinically feasible; treating with conventional higher doses of GH; and, when possible, minimizing the dose of spinal RT.
  • [MeSH-major] Body Height / drug effects. Gonadotropin-Releasing Hormone / analogs & derivatives. Growth Hormone / therapeutic use. Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15356041.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U24-CA55727
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone; 79561-22-1 / LHRH, Ala(6)-Gly(10)-ethylamide-; 9002-72-6 / Growth Hormone
  •  go-up   go-down


21. Cacheux W, Gourmel B, Alexandre J, Germann N, Rabillon F, Duffau B, Goldwasser F: An original administration of ifosfamide given once every other week: a clinical and pharmacological study. Anticancer Drugs; 2008 Mar;19(3):295-302
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An original administration of ifosfamide given once every other week: a clinical and pharmacological study.
  • Ifosfamide (IFOS) is a bifunctional alkylator with a wide spectrum of activity in solid tumors and has an autoinductive liver metabolism through P450 cytochromes.
  • Autoinduction might permit a better therapeutic index for combination therapy.
  • A phase I trial was investigated with interpatient dose escalation of a single dose of IFOS given every 2 weeks in advanced solid tumor patients.
  • The primary tumor was most often ovarian (5), peritoneal (3), sarcoma (2), melanoma (2) or miscellaneous (8).
  • The toxicity profile allows the development of bi-weekly IFOS-based combination therapies.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Ifosfamide / administration & dosage. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Area Under Curve. Chromatography, Gas. Cytochrome P-450 Enzyme System / drug effects. Dose-Response Relationship, Drug. Enzyme Induction / drug effects. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510176.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 9035-51-2 / Cytochrome P-450 Enzyme System; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


22. Kurbacher CM, Schmidt M, Kurbacher JA, Schäfer S, Arenz PN, Nagel WJ, Reinhold U: Bevacizumab (BEV) and continuous low-dose granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid tumors: final results of a prospective clinical trial. J Clin Oncol; 2009 May 20;27(15_suppl):e14544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab (BEV) and continuous low-dose granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid tumors: final results of a prospective clinical trial.
  • : e14544 Background: BEV is potent inhibitor of VEGF-mediated tumor angiogenesis.
  • METHODS: 26 pts have been enrolled: epithelial ovarian cancer, n=12; breast cancer, n= 6; primary peritoneal carcinoma, n=3; hormone-refractory prostate cancer, n=2; miscellaneous, n=3.
  • All pts have been considered refractory to or non-treatable by chemotherapy due to their baseline bone marrow and/or organ functions.
  • The median time to progression is 92 days and the median overall survival is 302 days.
  • CONCLUSIONS: BEV+GM-CSF is an active and generally well tolerated non-cytotoxic regimen in pts with advanced solid tumors.
  • Thus, large-scaled studies of this promising treatment are warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963617.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement